reports
Altimmune Announces Multiple Presentations at Upcoming American Diabet...
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association’s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under d...
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the...
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual recep...
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference (New Y...
Altimmune Announces First Quarter 2025 Financial Results and Business ...
Altimmune Announces First Quarter 2025 Financial Results and Business Update Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide...
Altimmune Secures Up to $100 Million in Credit Facility from Hercules ...
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility...
Altimmune Presents New Analyses Predicting High Rates of MASH Resoluti...
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlan...
Altimmune to Report First Quarter 2025 Financial Results and Provide B...
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at . Participants who would like to join the call may ...
Altimmune to Present at Upcoming EASL International Liver Congress™ 20...
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at ...
Altimmune to Participate in the Citizens Life Sciences Conference
Altimmune to Participate in the Citizens Life Sciences Conference GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows: Conference:Citizens Life Sciences ConferenceDate/Time:Wednesday, May 7, 2025, at 9:30 a.m. EDT The session will be webcast and can be accessed by visiting the section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage...
Altimmune Inc: 1 director
A director at Altimmune Inc maiden bought 10,000 shares at 5.200USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Altimmune to Host Virtual R&D Day on March 13, 2025
Altimmune to Host Virtual R&D Day on March 13, 2025 Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering t...
Altimmune to Participate in the Leerink Global Healthcare Conference
Altimmune to Participate in the Leerink Global Healthcare Conference GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference:Leerink Global Healthcare Conference Date/Time:Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the section of the Altimmune website. About Altimmune Altimmune is a late cli...
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Result...
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to...
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry D...
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GL...
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Result...
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at . Partici...
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows: Conference:Guggenheim SMID Cap Biotech Conference Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST The session will be webcast and can be accessed by visiting the section of the Altimmune website. About Altimmune ...
Altimmune Added to Nasdaq Biotechnology Index
Altimmune Added to Nasdaq Biotechnology Index GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant inflection points coming in 2025, including the topli...
Altimmune to Present at the Cachexia Regulatory & Trials Update Worksh...
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference o...
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Annual Evercore HealthCONx Conference (Coral Gables, FL)Tuesday, December 3, 2024Fireside Chat at 10:50 a.m. Eastern Time Piper Sandler Annual Healthcare Conference (New York, NY)Wednesday, December 4, 2024Fireside Chat at 3:30 p.m. Eastern Time The sessions will b...
Altimmune Announces Third Quarter 2024 Financial Results and Provides ...
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, November 12,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.